REGN is in a moderate uptrend
+57
BearishSidewaysBullish
Why this reading
- Price is above its 200-day average ($735.43).
- Price is above its 50-day average ($791.33).
- 50-day average is above the 200-day (long-term structure is up).
- MACD momentum is improving and the MACD line is above zero.
- Recent swings show higher highs and higher lows.
- The 50-day average is rising (+0.04%/day).
Price chart
Lower pane: RSI (14) with 70 and 30 marked. Arrows mark candlestick patterns.
Indicators
| Indicator | Value | Reading | What it means |
|---|---|---|---|
| Moving averages | Mixed | Neutral | 20-day $779.45, 50-day $791.33, 200-day $735.43 |
| RSI (14) | 62.0 | Bullish | Buyers have the upper hand. |
| MACD (12,26,9) | +5.21 | Bullish | MACD is above its signal line. |
| Bollinger %B | 0.82 | Neutral | Bands are 15.7% wide. |
| Volatility (ATR 14) | $18.43 (2.2%) | Neutral | Typical daily volatility. |
| Volume vs 20d avg | 0.61× | Neutral | Normal participation. |
| 52-week range | 86% | Bullish | Low $590.96, high $858.17 |
Key levels
- $852.34Resistance, 2 touches+3.8%
- $821.00Last close
- $817.97Support, 2 touches-0.4%
- $725.36Support, 2 touches-11.7%
- $641.76Support, 3 touches-21.8%
Recent candlestick patterns
No classic candlestick patterns in the last 20 sessions.
Latest news
- Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals to $850 From $900fiscal.ai
- Canaccord Genuity Raises Price Target for Regeneron Pharmaceuticalsfiscal.ai
- Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Yearsbenzinga
- Regeneron Secures $270 Million U.S. Contract Extension for Ebola Treatment Inmazebfiscal.ai
- Regeneron Announces Long-Term Phase 3 C-POST Trial Data for Libtayo in High-Risk CSCCfiscal.ai